In an international study led by UCLA, researchers have shown that giredestrant, a next-generation oral selective estrogen ...

In the CAPItello-291 trial of capivasertib plus fulvestrant, 73% of patients had already received a CDK4/6 inhibitor. As ...

At the San Antonio Breast Cancer Symposium, investigators reported phase III results showing that the oral selective estrogen ...

Highlights of the conference coverage from the 2025 European Society of Medical Oncology (ESMO) Congress included content on ...

Endocrine-disrupting chemicals (EDCs) are a class of chemicals that mimic, block or interfere with the production, metabolism or action of hormones in the body. As EDCs are ubiquitous in our ...

Sacituzumab govitecan failed to extend PFS in patients with hormone receptor-positive, HER2-negative breast cancer following endocrine therapy, according to data from San Antonio Breast Cancer ...

Multiple endocrine neoplasia type 2 (MEN2) is a rare hereditary disorder that affects the endocrine glands. Doctors mainly associate MEN2 with tumors of the adrenal gland, the thyroid, and the ...

Researchers report links between third-trimester exposure to endocrine disruptors and higher behavioural risk scores in early childhood.

A class of chemicals –– likely in products all over many homes in the United States –– could be impacting your hormone health. The scientific literature around EDCs is still growing, but associations ...

Endocrine disruptors are substances that interfere with the endocrine system. They are present in products such as food and beverage packaging, cosmetics, and flame-retardant chemicals. The endocrine ...

Endocrine therapies that target oestrogen action (anti-oestrogens and aromatase inhibitors) are widely used and successful breast cancer therapies, but many women treated with these therapies will ...